Tissue-specific promoters in gene therapy for the treatment of prostate cancer

T. Shirakawa, A. Gotoh, Y. Wada, S. Kamidono, S. C. Ko, Chinghai Kao, Thomas Gardner, L. W K Chung

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Delivery of therapeutic toxic genes to and their expression in tumor cells through the use of tissue-specific promoters could decrease their toxic effect on neighboring normal cells when virus-mediated gene delivery results in their infection. We have demonstrated the utility of two prostate cancer- specific promoters, long PSA and osteocalcin, for tissue-specific toxic gene therapy for prostate cancer. The two promoters were highly active in both androgen-dependent and androgen-independent prostate cancer cells. We also introduce the Phase I trial of osteocalcin promoter-based toxic gene therapy for bone metastases of prostate cancer, which is in progress at the University of Virginia.

Original languageEnglish
Pages (from-to)73-82
Number of pages10
JournalMolecular Urology
Volume4
Issue number2
StatePublished - 2000

Fingerprint

Poisons
Genetic Therapy
Prostatic Neoplasms
Osteocalcin
Androgens
Therapeutics
Genes
Neoplasm Metastasis
Viruses
Bone and Bones
Infection
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Shirakawa, T., Gotoh, A., Wada, Y., Kamidono, S., Ko, S. C., Kao, C., ... Chung, L. W. K. (2000). Tissue-specific promoters in gene therapy for the treatment of prostate cancer. Molecular Urology, 4(2), 73-82.

Tissue-specific promoters in gene therapy for the treatment of prostate cancer. / Shirakawa, T.; Gotoh, A.; Wada, Y.; Kamidono, S.; Ko, S. C.; Kao, Chinghai; Gardner, Thomas; Chung, L. W K.

In: Molecular Urology, Vol. 4, No. 2, 2000, p. 73-82.

Research output: Contribution to journalArticle

Shirakawa, T, Gotoh, A, Wada, Y, Kamidono, S, Ko, SC, Kao, C, Gardner, T & Chung, LWK 2000, 'Tissue-specific promoters in gene therapy for the treatment of prostate cancer', Molecular Urology, vol. 4, no. 2, pp. 73-82.
Shirakawa T, Gotoh A, Wada Y, Kamidono S, Ko SC, Kao C et al. Tissue-specific promoters in gene therapy for the treatment of prostate cancer. Molecular Urology. 2000;4(2):73-82.
Shirakawa, T. ; Gotoh, A. ; Wada, Y. ; Kamidono, S. ; Ko, S. C. ; Kao, Chinghai ; Gardner, Thomas ; Chung, L. W K. / Tissue-specific promoters in gene therapy for the treatment of prostate cancer. In: Molecular Urology. 2000 ; Vol. 4, No. 2. pp. 73-82.
@article{d5164d7d67934e428395c86aa4c40cf5,
title = "Tissue-specific promoters in gene therapy for the treatment of prostate cancer",
abstract = "Delivery of therapeutic toxic genes to and their expression in tumor cells through the use of tissue-specific promoters could decrease their toxic effect on neighboring normal cells when virus-mediated gene delivery results in their infection. We have demonstrated the utility of two prostate cancer- specific promoters, long PSA and osteocalcin, for tissue-specific toxic gene therapy for prostate cancer. The two promoters were highly active in both androgen-dependent and androgen-independent prostate cancer cells. We also introduce the Phase I trial of osteocalcin promoter-based toxic gene therapy for bone metastases of prostate cancer, which is in progress at the University of Virginia.",
author = "T. Shirakawa and A. Gotoh and Y. Wada and S. Kamidono and Ko, {S. C.} and Chinghai Kao and Thomas Gardner and Chung, {L. W K}",
year = "2000",
language = "English",
volume = "4",
pages = "73--82",
journal = "Molecular Urology",
issn = "1091-5362",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Tissue-specific promoters in gene therapy for the treatment of prostate cancer

AU - Shirakawa, T.

AU - Gotoh, A.

AU - Wada, Y.

AU - Kamidono, S.

AU - Ko, S. C.

AU - Kao, Chinghai

AU - Gardner, Thomas

AU - Chung, L. W K

PY - 2000

Y1 - 2000

N2 - Delivery of therapeutic toxic genes to and their expression in tumor cells through the use of tissue-specific promoters could decrease their toxic effect on neighboring normal cells when virus-mediated gene delivery results in their infection. We have demonstrated the utility of two prostate cancer- specific promoters, long PSA and osteocalcin, for tissue-specific toxic gene therapy for prostate cancer. The two promoters were highly active in both androgen-dependent and androgen-independent prostate cancer cells. We also introduce the Phase I trial of osteocalcin promoter-based toxic gene therapy for bone metastases of prostate cancer, which is in progress at the University of Virginia.

AB - Delivery of therapeutic toxic genes to and their expression in tumor cells through the use of tissue-specific promoters could decrease their toxic effect on neighboring normal cells when virus-mediated gene delivery results in their infection. We have demonstrated the utility of two prostate cancer- specific promoters, long PSA and osteocalcin, for tissue-specific toxic gene therapy for prostate cancer. The two promoters were highly active in both androgen-dependent and androgen-independent prostate cancer cells. We also introduce the Phase I trial of osteocalcin promoter-based toxic gene therapy for bone metastases of prostate cancer, which is in progress at the University of Virginia.

UR - http://www.scopus.com/inward/record.url?scp=0034046855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034046855&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 73

EP - 82

JO - Molecular Urology

JF - Molecular Urology

SN - 1091-5362

IS - 2

ER -